Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus salivarius BLIS M18 + Lactobacillus reuteri LR08 + Lactobacillus paracasei Lpc-37
- Development stage
- Unknown
- Lead developer
- BLIS Technologies
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This investigational combination therapy, developed by researchers at Ain Shams University, consists of three probiotic bacterial strains—*Streptococcus salivarius* BLIS M18, *Lactobacillus reuteri* LR08, and *Lactobacillus paracasei* Lpc-37—formulated with a prebiotic. It is specifically designed to treat extrinsic black tooth stains (tooth discoloration) in children by targeting and inhibiting the growth of chromogenic bacteria. The primary biological targets are *Aggregatibacter actinomycetemcomitans* and *Actinomyces naeslundii*, which are implicated in the formation of these stains. In a Phase 4 clinical trial, the probiotic administration resulted in the complete eradication of *A. actinomycetemcomitans* and a significant reduction in *A. naeslundii* levels within 14 days, demonstrating potent bactericidal effects in the oral microbiome.
- Other names
- Probiotic with PrebioticProbiotics for Black Tooth Stains
Beyond the preview
Go deeper on Streptococcus salivarius BLIS M18 + Lactobacillus reuteri LR08 + Lactobacillus paracasei Lpc-37.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Streptococcus salivarius BLIS M18 + Lactobacillus reuteri LR08 + Lactobacillus paracasei Lpc-37.